Swine Bibliography Centre
|
Support that keeps you updated for FREE  |
Bulletin No. 26 - Fall 2006
BacterologyMycoplasma hyopneumoniae
ROYER G, CHARREYRE C, MILWARD F
Efficacy and safety of needle-free transdermal delivery of a novel Mycoplasma hyopneumoniae bacterin.
American Association of Swine Veterinarians - Proceedings, 2006, 239-241
Forty-eight piglets originating from a low Mycoplasma hyopneumoniae incidence herd were vaccinated before 3 weeks of age (16-19 days of age) with a M. hyopneumoniae bacterin (Day 0) administered using a needle-free system, the Derma-VacTM NF Transdermal Vaccinator System, or kept as controls. All pigs were subsequently challenged on day 160, 161 and 162 by the intranasal route with lung homogenate and previously frozen culture of M. hyopneumoniae and necropsied one month later. The mean percentage of pneumonic tissue was establish for both vaccinated and control groups. The results show that vaccinated pigs had significantly less pneumonic lesions than control pigs (1.72% versus 4.35%) and underline the efficacy of the Derma-VacTM system. Moreover, a study conducted in 663 pigs vaccinated with the Derma-VacTM system confirmed its safety as well.
